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Epidemiology and Classification
The World Health Organization (WHO) 
estimates that over 3 million people (9% of 
global blindness) are blinded by age-related 
macular degeneration (AMD). AMD affects 
people over the age of 55. There are two 
main types of AMD, dry and wet. In dry AMD, 
patients slowly lose vision through progressive 
atrophy of the macular tissue. Wet, or 
exudative, AMD, is associated with new 
blood vessels called subretinal neovascular 
membranes (or SRNVM) and affected 
patients lose vision more rapidly due to fluid 
leakage and haemorrhage at the macula. 
Recent developments in genetics
Originally, AMD was thought to be a degen-
erative disease with a genetic component, 
but strongly influenced by environmental 
factors, especially smoking. This changed in 
2005, with the demonstration that a gene 
(complement factor H or CFH, a regulator of 
inflammation) is implicated in up to 50% of 
cases of AMD in some populations.1 This 
suggests that AMD may be associated with 
inflammatory processes rather than 
primarily being an environmentally deter-
mined degenerative disease.
Since then, other genes, predominantly 
associated with inflammation, have been 
linked to AMD: some increase the risk of 
AMD and others protect against it. These 
genes are markers of risk for both wet and 
dry AMD. Their prevalence varies between 
different ethnic groups.2 
It is still not understood why an individual 
at risk will manifest dry or wet AMD; at 
present, the only known trigger for wet AMD 
is smoking – an environmental factor. 
New treatments for SRNVM in wet AMD
Although, there is still no effective therapy 
for dry AMD, new and more effective treat-
ments for wet AMD have been developed.
Initial treatment protocols for SRNVM 
were restricted to thermal laser3 and, subse-
quently, photodynamic therapy (PDT).4 
Though thermal laser was cheap to deliver, 
few patients were eligible for treatment and 
recurrence after laser was common. 
PDT allowed more patients to be treated, 
but the usual outcome was delayed vision 
loss rather than visual improvement. 
The identification of the crucial role 
played by vascular endothelial growth factor 
(VEGF) in the pathogenesis of wet AMD has 
allowed the development of VEGF-blocking 
agents such as bevacizumab (Avastin), 
pegaptanib (Macugen) and ranibizumab 
(Lucentis).5 This is the first generation of 
drugs which start to control the vision loss 
from late disease in all types of wet AMD 
and, in some cases, to produce 
improvement.6 
Macugen was shown to be more effective 
than PDT in treating wet AMD and to reduce 
the probability of developing severe vision 
loss (by about 50% over one year). However, 
like PDT, it only delayed vision loss but did 
not prevent it. 
Subsequently, it was shown that Lucentis 
was more effective than Macugen and could 
prevent further vision loss: about 95% of 
patients maintained their baseline vision 
whilst on treatment. Furthermore, one third 
of patients experienced a gain of vision 
(more than 15 letters of visual acuity). 
In 2005, it was demonstrated that 
Avastin, the molecule from which Lucentis is 
derived, could also be used for the 
treatment of wet AMD,7 although this was 
not its original use. Since then, the use of 
Avastin for the treatment of AMD has been 
widely reported; the literature suggests that 
its efficacy is similar to that of Lucentis, as 
well as its toxicity. The advantages of Avastin 
are a lower cost and longer half-life (allowing 
for six-weekly dosing, rather than four-
weekly as for Lucentis). 
Combination treatment protocols
Possibly the most important recent addition 
to treatment protocols for wet AMD is the 
combination of two, or even three, modalities 
delivered simultaneously to minimise 
re-treatments and optimise gain in visual 
acuity. Intravitreal anti-VEGF agents have 
been combined with intravitreal steroids 
(either dexamethasone or triamcinolone) 
and, in some cases, in combination with PDT. 
This is called ‘triple therapy’. There are some 
reports suggesting that these triple treat-
ments may reduce the need for re-treatment 
and may provide a ‘one shot’ treatment.
Polypoidal chorio-vasculopathy
Recently, a subset of wet AMD, termed 
polypoidal chorio-vasculopathy (PCV), has 
been identified as a clinical entity.8 PCV is 
important, as it may be the main cause of 
vision loss from AMD in certain Asian and 
black populations.8 It has a different natural 
history, treatment, and prognosis relative to 
traditional wet AMD. 
PCV is best demonstrated by ICG 
(indocyanine green) angiography, while 
wet AMD is shown with fluorescein. The 
distinctive clinical features of PCV include 
one or more haemorrhagic pigment epithelial 
detachments (PEDs), extensive exudation, 
and disease outside of the macula including 
the periphery. There is a predilection for 
peripapillary ‘polyps’. Patients are also 
characteristically younger. 
Current treatments include: direct laser 
ablation of choroidal polyps9 seen on ICG 
angiography, PDT, and intravitreal anti-VEGF 
drugs – or a combination of all of these. 
There is no consensus regarding treatment 
protocol, but there are series reporting each 
modality as being effective. For a clinician, it 
is critical to suspect PCV from the clinical 
picture and the ethnicity of the patient, and 
then to investigate appropriately with ICG 
and identify the polyps for treatment.
Conclusion
Over the last four years, age-related macular 
degeneration has become better under-
stood and treatments have become much 
more effective. The demonstration of high-risk 
genes associated with the inflammation 
process has changed the approach to this 
disease. Also, the identification of VEGF as 
central to the pathogenesis of wet AMD has 
allowed the development of the first gener-
ation of drugs that start to control the vision 
loss from late disease. In the future, we
may be able to identify at-risk individuals 
and, as well as stopping smoking, suggest 
other changes in lifestyle and perhaps 
offer long-term medication that can prevent 
the disease.
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